Wagaskar, Vinayak G.
Zaytoun, Osama
Kale, Priyanka
Pedraza, Adriana
Haines, Kenneth III
Tewari, Ash
Article History
Received: 17 September 2022
Accepted: 30 December 2022
First Online: 16 March 2023
Declarations
:
: Dr Ash Tewari has served as a site-PI on pharma/industry-sponsored clinical trials from Kite Pharma, Lumicell Inc, Dendreon, and Oncovir Inc. He has received research funding (grants) to his institution from DOD, NIH, Axogen, Intuitive Surgical, AMBFF, and other philanthropy. Dr Ash Tewari has served as an unpaid consultant to Roivant Biosciences and advisor to Promaxo. He owns equity in Promaxo. Rest of the authors don’t have conflicts of interests.
: This retrospective study was approved by the Institutional Review Board (GCO#14–0175) of the Icahn School of Medicine at Mount Sinai within the Mount Sinai Health System in New York City.